Magnesium Sulfate in Obese Preeclamptics

Status Completed

Clinical Trial Summary

Clinical Trial Description

The purpose of this study is to learn how medications participant will receive in the course of their delivery are metabolized (broken down by the body). The investigators hope to learn more about the way drugs are metabolized by pregnant women, and how those drugs are distributed in the blood and body compartments and cleared in the urine, and how maternal body weight affects the metabolism. With this information the investigators will be able to develop a treatment regimen considering factors in the body that affect magnesium levels so that the investigators can improve treatment of pregnant women. The goal of the study is to understand how different dosing of magnesium sulfate affects blood levels of the magnesium in larger women.

Magnesium sulfate is generally given to patients to protect the mother against seizures in the case of preeclampsia. Different hospitals in the United States use different doses of magnesium sulfate. Participants will receive one of two accepted doses of magnesium sulfate for preeclampsia. The dose is usually 4g - 6g at the start, with another dose of 2-3 g every hour until 24 hours after delivery. Participants will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete. Participants will receive magnesium sulfate in the course of their normal clinical care whether or not they participate in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02835339
Study type	Interventional
Source	Oregon Health and Science University
Contact
Status	Completed
Phase	Phase 4
Start date	July 12, 2016
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03510286` - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting	`NCT03313024` - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting	`NCT04990141` - Molecular Screening Method for Preeclampsia (PREMOM)
Completed	`NCT02147626` - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia	N/A
Not yet recruiting	`NCT05999851` - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy	N/A
Recruiting	`NCT02923206` - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis	N/A
Withdrawn	`NCT05016440` - Lisinopril for Renal Protection in Postpartum Preeclamptic Women	N/A
Not yet recruiting	`NCT02541110` - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler	N/A
Completed	`NCT02854501` - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Terminated	`NCT02558023` - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine	Phase 3
Completed	`NCT02554604` - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Completed	`NCT02384226` - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Recruiting	`NCT02337049` - Preeclampsia Subtypes and Surrogate Markers of CVD Risk	N/A
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed	`NCT02238704` - Cornell University-Micronutrient Initiative Calcium Supplementation Study	N/A
Withdrawn	`NCT01179542` - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR	N/A
Completed	`NCT01195441` - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound	N/A
Completed	`NCT00456118` - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting	`NCT00117546` - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.